Benzinga | Jun 25, 2021 07:30AM EDT

BioMarin Receives Positive CHMP Opinion In Europe For Vosoritide For Treatment Of Children With Achondroplasia From Age 2 Until Growth Plates Close

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for vosoritide, a once daily injection analog of C-type Natriuretic Peptide (CNP) to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height. Achondroplasia is the most common form of disproportionate short stature in humans. A final approval decision, typically consistent with the CHMP recommendation, is expected from the European Commission in Q3 2021. Vosoritide is potentially the first medicine to be approved to treat children with achondroplasia in Europe and would be marketed under the brand name VOXZOGO(tm) (vosoritide).